Sky News host Gabriella Power discusses the “plummet” in Pfizer and Moderna stocks following RFK Jr clearing a Senate vote ...

Loading But Tiba says it needs access to an mRNA manufacturing facility in Australia to make the vaccines at a commercial scale on our shores. The Moderna rejection has forced the company and the ...

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

There is no antiviral treatment for the miserable but thankfully short-lived illness, and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its vaccines against Covid-19 and respiratory syncytial virus continue to ...

Moderna is recruiting adult participants for Nova 301, its Phase 3 clinical trial evaluating an investigational norovirus vaccine called mRNA-1403.

Moderna (MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine. The company now expects $1.5 billion to $2 ...

Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people worldwide every year, and though there is currently no preventive vaccine ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...